Literature DB >> 8312775

Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections.

R J Körner1, D S Reeves, A P MacGowan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8312775      PMCID： PMC2542530          DOI： 10.1136/bmj.308.6922.191

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

Authors:  E Pérez-Trallero; J M Garcia-Arenzana; J A Jimenez; A Peris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  Penetration of ciprofloxacin into bronchial secretions.

Authors:  E Bergogne-Bérézin; G Berthelot; P Even; M Stern; P Reynaud
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Inappropriate use of oral ciprofloxacin.

Authors:  T R Frieden; R J Mangi
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

4.  Prospective study of the aetiology and outcome of pneumonia in the community.

Authors:  M A Woodhead; J T Macfarlane; J S McCracken; D H Rose; R G Finch
Journal:  Lancet       Date:  1987-03-21       Impact factor: 79.321

5.  Severe community-acquired pneumonia. Epidemiology and prognostic factors.

Authors:  A Torres; J Serra-Batlles; A Ferrer; P Jiménez; R Celis; E Cobo; R Rodriguez-Roisin
Journal:  Am Rev Respir Dis       Date:  1991-08

6.  Surveillance of Mycoplasma pneumoniae infections in Scotland 1986-1991.

Authors:  K Ghosh; G B Clements
Journal:  J Infect       Date:  1992-09       Impact factor: 6.072

7.  Capsular types of Streptococcus pneumoniae isolated from blood and CSF during 1982-1987.

Authors:  S V Nielsen; J Henrichsen
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079
  7 in total
  12 in total

Review 1.  The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

Authors:  P J Moss; R G Finch
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin.

Authors:  Estelle Marrer; A Tatsuo Satoh; Margaret M Johnson; Laura J V Piddock; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Whatalotwegot--the messages in drug advertisements.

Authors:  R E Ferner; D K Scott
Journal:  BMJ       Date:  1994 Dec 24-31

4.  Fluoroquinolones in upper respiratory tract infections.

Authors:  M Spiteri
Journal:  BMJ       Date:  1994-03-05

5.  Ciprofloxacin in general practice.

Authors:  P M Donaldson; A P Pallett; M P Carroll
Journal:  BMJ       Date:  1994-05-28

6.  Fluoroquinolones in chronic obstructive pulmonary disease.

Authors:  A Colville; M Knowles; D Large; J George; P Mustchin
Journal:  BMJ       Date:  1994-05-28

7.  The Role of Quinolones in Upper Respiratory Tract Infections.

Authors:  Ronald F. Grossman
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

8.  Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  L M Weigel; G J Anderson; R R Facklam; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 9.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 10.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.